About Us

Publications

BMT CTN investigators have published >135 manuscripts, including >30 primary study results papers, in numerous peer-reviewed journals, including the New England Journal of Medicine, Journal of Clinical Oncology, and Blood. Selected publications are summarized for dissemination to patients and the lay public.

Note: Some Publications were unable to be listed below - please see that listing here. All other publications based on PubMedIDs are listed below.

 

Found 139 results
2021
L. J. Costa, Derman, B. A., Bal, S., Sidana, S., Chhabra, S., Silbermann, R., Ye, J. C., Cook, G., Cornell, R. F., Holstein, S. A., Shi, Q., Omel, J., Callander, N. S., Chng, W. Joo, Hungria, V., Maiolino, A., Stadtmauer, E., Giralt, S., Pasquini, M., Jakubowiak, A. J., Morgan, G. J., Krishnan, A., Jackson, G. H., Mohty, M., Mateos, M. Victoria, Dimopoulos, M. A., Facon, T., Spencer, A., San Miguel, J., Hari, P., Usmani, S. Z., Manier, S., McCarthy, P., Kumar, S., Gay, F., and Paiva, B., International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials., Leukemia, vol. 35, no. 1, pp. 18-30, 2021.
B. L. Scott, Pasquini, M. C., Fei, M., Fraser, R., Wu, J., Devine, S. M., Porter, D. L., Maziarz, R. T., Warlick, E., Fernandez, H. F., Soiffer, R. J., Alyea, E., Hamadani, M., Bashey, A., Giralt, S., Geller, N. L., Leifer, E., Hourigan, C. S., Gui, G., Mendizabal, A., Horowitz, M. M., H Deeg, J., and Horwitz, M. E., Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial., Transplant Cell Ther, vol. 27, no. 6, pp. 483.e1-483.e6, 2021.
H. T. Kim, Logan, B., and Weisdorf, D. J., Novel Composite Endpoints after Allogeneic Hematopoietic Cell Transplantation., Transplant Cell Ther, vol. 27, no. 8, pp. 650-657, 2021.
M. J. Martens and Logan, B. R., A unified approach to sample size and power determination for testing parameters in generalized linear and time-to-event regression models., Stat Med, vol. 40, no. 5, pp. 1121-1132, 2021.
B. C. Tilley, Mainous, A. G., Amorrortu, R. P., M McKee, D., Smith, D. W., Li, R., DeSantis, S. M., Vernon, S. W., Koch, G., Ford, M. E., Diaz, V., and Alvidrez, J., Using increased trust in medical researchers to increase minority recruitment: The RECRUIT cluster randomized clinical trial., Contemp Clin Trials, vol. 109, p. 106519, 2021.
2020
O. Shah, Tamaresis, J. S., Kenyon, L. Jean, Xu, L., Zheng, P., Gupta, P., Rangarajan, K., Lee, S., Spellman, S., Nikiforow, S., Zehnder, J., and Meyer, E. H., Analysis of the Whole CDR3 T Cell Receptor Repertoire after Hematopoietic Stem Cell Transplantation in 2 Clinical Cohorts., Biol Blood Marrow Transplant, vol. 26, no. 6, pp. 1050-1070, 2020.
J. Pidala, Martens, M., Anasetti, C., Carreras, J., Horowitz, M., Lee, S. J., Antin, J., Cutler, C., and Logan, B., Factors Associated With Successful Discontinuation of Immune Suppression After Allogeneic Hematopoietic Cell Transplantation., JAMA Oncol, vol. 6, no. 1, p. e192974, 2020.
L. F. Newell, DeFor, T. E., Cutler, C., Verneris, M. R., Blazar, B. R., Miller, J. S., Antin, J. H., Howard, A., Wu, J., MacMillan, M. L., Panoskaltsis-Mortari, A., Weisdorf, D. J., and Holtan, S. G., Follistatin and Soluble Endoglin Predict 1-Year Nonrelapse Mortality after Allogeneic Hematopoietic Cell Transplantation., Biol Blood Marrow Transplant, vol. 26, no. 3, pp. 606-611, 2020.
M. J. Martens and Logan, B. R., Group sequential tests for treatment effect on survival and cumulative incidence at a fixed time point., Lifetime Data Anal, vol. 26, no. 3, pp. 603-623, 2020.
C. S. Hourigan, Dillon, L. W., Gui, G., Logan, B. R., Fei, M., Ghannam, J., Li, Y., Licon, A., Alyea, E. P., Bashey, A., H Deeg, J., Devine, S. M., Fernandez, H. F., Giralt, S., Hamadani, M., Howard, A., Maziarz, R. T., Porter, D. L., Scott, B. L., Warlick, E. D., Pasquini, M. C., and Horwitz, M. E., Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease., J Clin Oncol, vol. 38, no. 12, pp. 1273-1283, 2020.
L. J. Costa, Iacobelli, S., Pasquini, M. C., Modi, R., Giaccone, L., Blade, J., Schonland, S., Evangelista, A., Perez-Simon, J. A., Hari, P., Brown, E. E., Giralt, S. A., Patriarca, F., Stadtmauer, E. A., Rosinol, L., Krishnan, A. Y., Gahrton, G., and Bruno, B., Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation., Bone Marrow Transplant, vol. 55, no. 9, pp. 1810-1816, 2020.
Z. DeFilipp, Burns, L. J., Jaglowski, S. M., Leppin, A. L., Pavletic, S., Waldman, B., Weisdorf, D. J., Wood, W. A., and Khera, N., A New Standard in Graft-versus-Host Disease Prophylaxis? An Introduction to Blood and Marrow Transplant Clinical Trials Network 1703., Biol Blood Marrow Transplant, vol. 26, no. 12, pp. e305-e308, 2020.
J. E. Levine, Antin, J. H., Allen, C. E., Burroughs, L. M., Cooke, K. R., Devine, S., Heslop, H., Nakamura, R., Talano, J. An, Yanik, G., and DiFronzo, N., Priorities for Improving Outcomes for Nonmalignant Blood Diseases: A Report from the Blood and Marrow Transplant Clinical Trials Network., Biol Blood Marrow Transplant, vol. 26, no. 5, pp. e94-e100, 2020.
J. Pidala, Hamadani, M., Dawson, P., Martens, M., Alousi, A. M., Jagasia, M., Efebera, Y. A., Chhabra, S., Pusic, I., Holtan, S. G., Ferrara, J. L. M., Levine, J. E., Mielcarek, M., Anasetti, C., Antin, J. H., Bolaños-Meade, J., Howard, A., Logan, B. R., Leifer, E. S., Pritchard, T. S., Horowitz, M. M., and MacMillan, M. L., Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial., Blood, vol. 135, no. 2, pp. 97-107, 2020.
S. A. Holstein, Howard, A., Avigan, D., Bhutani, M., Cohen, A. D., Costa, L. J., Dhodapkar, M. V., Gay, F., Gormley, N., Green, D. J., Hillengass, J., Korde, N., Li, Z., Mailankody, S., Neri, P., Parekh, S., Pasquini, M. C., Puig, N., G Roodman, D., Samur, M. Kemal, Shah, N., Shah, U. A., Shi, Q., Spencer, A., Suman, V. J., Usmani, S. Z., and McCarthy, P. L., Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling., Biol Blood Marrow Transplant, vol. 26, no. 10, pp. e247-e255, 2020.
S. A. Holstein, Al-Kadhimi, Z., Costa, L. J., Hahn, T., Hari, P., Hillengass, J., Jacob, A., Munshi, N. C., Oliva, S., Pasquini, M. C., Shi, Q., Stadtmauer, E. A., Waldvogel, S. L., and McCarthy, P. L., Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling., Biol Blood Marrow Transplant, vol. 26, no. 1, pp. e7-e15, 2020.
S. Giralt, Costa, L. J., Maloney, D., Krishnan, A., Fei, M., Antin, J. H., Brunstein, C., Geller, N., Goodman, S., Hari, P., Logan, B., Lowsky, R., Qazilbash, M. H., Sahebi, F., Somlo, G., Rowley, S., Vogl, D. T., Vesole, D. H., Pasquini, M., and Stadtmauer, E., Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial., Biol Blood Marrow Transplant, vol. 26, no. 4, pp. 798-804, 2020.
2019
R. F. Ambinder, Wu, J., Logan, B., Durand, C. M., Shields, R., Popat, U. R., Little, R. F., McMahon, D. K., Cyktor, J., Mellors, J. W., Ayala, E., Kaplan, L. D., Noy, A., Jones, R. J., Howard, A., Forman, S. J., Porter, D., Arce-Lara, C., Shaughnessy, P., Sproat, L., Hashmi, S. K., Mendizabal, A. M., Horowitz, M. M., Navarro, W. H., and Alvarnas, J. C., Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies: The BMT CTN-0903/AMC-080 Trial., Biol Blood Marrow Transplant, vol. 25, no. 11, pp. 2160-2166, 2019.
A. Rashidi, Shanley, R., Anasetti, C., Waller, E. K., Scott, B. L., Blazar, B. R., and Weisdorf, D. J., Analysis of BMT CTN-0201 and -0901 samples did not reproduce the reported association between recipient REG3A rs7588571 and chronic GVHD., Bone Marrow Transplant, vol. 54, no. 3, pp. 490-493, 2019.
A. Rashidi, Luo, X., Cooley, S., Anasetti, C., Waller, E. K., Brunstein, C. G., Cichocki, F., Weisdorf, D. J., and Miller, J. S., The association of CMV with NK-cell reconstitution depends on graft source: results from BMT CTN-0201 samples., Blood Adv, vol. 3, no. 16, pp. 2465-2469, 2019.
E. A. Stadtmauer, Pasquini, M. C., Blackwell, B., Hari, P., Bashey, A., Devine, S., Efebera, Y., Ganguly, S., Gasparetto, C., Geller, N., Horowitz, M. M., Koreth, J., Knust, K., Landau, H., Brunstein, C., McCarthy, P., Nelson, C., Qazilbash, M. H., Shah, N., Vesole, D. H., Vij, R., Vogl, D. T., Giralt, S., Somlo, G., and Krishnan, A., Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial., J Clin Oncol, vol. 37, no. 7, pp. 589-597, 2019.
J. Paul, Nakasone, H., Sahaf, B., Wu, F., Wang, K., Ho, V., Wu, J., Kim, H., Blazar, B., Ritz, J., Howard, A., Cutler, C., and Miklos, D., A confirmation of chronic graft--host disease prediction using allogeneic HY antibodies following sex-mismatched hematopoietic cell transplantation., Haematologica, vol. 104, no. 7, pp. e314-e317, 2019.
M. Gooptu, Kim, H. T., Howard, A., Choi, S. W., Soiffer, R. J., Antin, J. H., Ritz, J., and Cutler, C. S., Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clini, Biol Blood Marrow Transplant, vol. 25, no. 11, pp. 2143-2151, 2019.
M. J. Levis, Bin Chen, Y. -, Hamadani, M., Horowitz, M. M., and Jones, R. J., FLT3 Inhibitor Maintenance After Allogeneic Transplantation: Is a Placebo-Controlled, Randomized Trial Ethical?, J Clin Oncol, vol. 37, no. 19, pp. 1604-1607, 2019.
A. A. King, McKinstry, R. C., Wu, J., Eapen, M., Abel, R., Varughese, T., Kamani, N., and Shenoy, S., Functional and Radiologic Assessment of the Brain after Reduced-Intensity Unrelated Donor Transplantation for Severe Sickle Cell Disease: Blood and Marrow Transplant Clinical Trials Network Study 0601., Biol Blood Marrow Transplant, vol. 25, no. 5, pp. e174-e178, 2019.